Entered into an exclusive licensing agreement with Cipla for irinotecan liposome injection
May 16, 2025
Source: drugdu
110
CSPC Pharmaceutical Group announced on the Hong Kong Stock Exchange that it has entered into an exclusive license agreement with Cipla USA, Inc. ("Cipla") for the commercialization of the company's irinotecan liposome injection in the United States. Under the terms of the agreement, the company agreed to grant Cipla an exclusive license to commercialize the product in the region. The company will receive an initial payment of US$15 million and is also entitled to receive potential first commercial sales and regulatory milestone payments of up to US$25 million and potential additional commercial sales milestone payments of up to US$1.025 billion, as well as double-digit tiered sales commissions based on the product's annual net sales in the region. Irinotecan is currently used to treat a variety of solid tumors, such as metastatic pancreatic cancer, colorectal cancer, lung cancer and cervical cancer, and is a component of a variety of combination therapies used to treat these types of cancers.
https://finance.eastmoney.com/a/202505153404987161.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Bedaquiline Fumarate API Approved for Marketing, Enriching Anti-TB Drug Product Line July 25, 2025
- Huadong Medicine’s subsidiary’s Caspofungin Acetate for Injection approved by the U.S. FDA July 25, 2025
- Good news from AstraZeneca July 25, 2025
- A breakthrough in the cure of hepatitis B is in sight, and the share prices of leading pharmaceutical companies have doubled July 25, 2025
- A new hotspot in the innovative drug market July 25, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
